earnings forward the excited much call. morning, be for to today truly to Good our joining everyone, contributing to our I'm Joe. you, very thank my you, look team here call. Integer and continued first join for and to again, I performance. And Thank
Let results. the quarter with of me financial start review third adjusted our
year sales, is which quarter both continues trend and up we this last a in $XXX organic delivered million growth on versus as X% Our reported basis.
adjusted up earnings XX% basis. on delivered is organically that X% a shortly growth million up single $XX the net in reported up up our all diluted and at million, this basis. $X.XX per X X performance. high which share, adjusted of product EBITDA see contributing are a $X.XX FX of You'll on or And followed we of year-over-year $XX digits lines income to quarter, adjusted Adjusted
Let provide sales our next these with on the some color me on trends slide. starting results,
meaningful and we the As a indicator believe page may X-quarter trailing our trend an in a purchasing contain market quarter is the reminder, of customer are this versus decision. organic resulting this sales. timing We of in that how performing growth anomalies individual shows more
growth product trailing trends And growth the the building medical As by we mentioned, though, a in X% of we nonmedical Integer line, decline offset is quarters. X-quarter X prior this show our across positive product lines, on partially enterprise. all our achieved in strong in
the your Slide of Now attention left side X. to turning
You'll headwind leverage on operating adjusted XX%. improved performance, increased higher year. last higher up EBITDA versus million expect or million by $X than quarter These compensation our well do Concurrent expense sales incentive $X total third we driven impact our $XX XXXX. see year-over-year, as improved $X be was compensation both our increased as reported were of XXXX favorable incentive with that offset this by a currency to from growth expense. million partially million from
drivers the continued additional leveraging, of the fall interest well the on with bridge income expense see net that adjusted income, in for $X next the benefit that in I'll debt year-over-year right page, $X of you the to quarter. take our expenses, we tax from EBITDA XX% net as an -- detail side improvement the million also million increased the as Turning the headwind still tax the talk bridge, effective you excuse slide. in but And to achieved to on more tax rate, me, complete through
Slide flow XX, I'd the the performance third to share cash our like quarter. Looking at in
some debt excess now, down repayments. As we our time we've continued for pay been of doing required to in
quarter, which interest on the $XXX in significantly remain this leverage, financial at proceeds cash and down XX loan from of the quarter. strong substantially cash agencies, from from highly generated leverage focused a rate free addition, strengthens $XXX debt, upgrades the received EBITDA million $XX million end of quarter $XX X.Xx from continue the times free loan third in term to of Surgical additional reduction the at A. reduction cash we beginning rating point And leverage including flow was sale, B. to Orthopedics term the our our drive the we million on the credit million of And from X.X & third the $XXX two million plus interest up With flow our X.X trend. Advanced adjusted Our continuing working capital. million year cash reduced basis $XX and the XX a of paid by end We quarter resulted $XXX rate an position. significantly from Reducing during flow. we our point on of major second million reduced from improved We basis operating of operations earned flow the to our
Now and product let's drive in replenishment. the line product top Vascular line by benefit primarily customer to our Cardio electrophysiology key with driven X% strong a is delivering quarter. continued strength results. inventory a Starting market year-over-year line turn with new the growth product Slide third launches XX, to growth, the & This of the continues sales of organic review in
continues segments, Our including key across structural upward and sales vascular. several demand quarterly trend with peripheral electrophysiology, heart strong
from market baseline, will high-growth low accelerating segments. product remain very focus the & will above line offset and of shows remain part not to XX% X grew than Neuromodulation Cardiac quarter. Medical given XX trend average enough growth increased tough on up of the was our Cardiac the the third devices will expect our of X% to We were Rhythm Sales at first in quarter, segment. these the comparable in Slide in growth single the XXXX through was a And quarters quarter growth Management Rhythm of increase demand, focused the high last and on demand. fourth we customers, higher from comparable. a fourth it sales finished in faces the digits, teens, we delivering driver key while challenging Neuromodulation the Cardiac of neuromodulation in XXXX. active fourth quarter support the spinal though revenue least CRM the year the a deliver from cord product stimulation third primarily quarter, over In Management grow
acquired ASO with today line. product Portable reminder, As Orthopedics shown includes Brian sales our a Surgical, Brian. supply our Advanced line & under The product Medical agreements
year-over-year quarter with expand Medical, Slide drilling energy the business product and market. to Electrochem third our level in first finally, exciting summarizes decline of half and customer Surgical its driven in and activity, market segment. growth above-market experienced off penetrate products. the Advanced by adjustment several due to Electrochem and was Electrochem, but And and battery in sales has military expected & more rechargeable a third Orthopedic of execute in Portable are in phaseout The trends. the saw The inventory trailing American initiatives strength nonmedical strategy a And while line sales new certain to sales XX products. be to further timing pack four-quarter flattens continues win offering, environmental North the quarter its planned with the
Let's full turn outlook. now the to year
sales our we guidance. As in revision are an upward Joe and mentioned, making earnings
$X.XXX of last to basis range sales, to a year. to growth expect we on adjusted For X% a billion of $X.XX a billion, comparable with X%
And a difficult the medical is stated, in comparable penetration have of year quarter a market. reflects As sales we our there consistently period. full strong very XXXX performance fourth represents despite,
exchange expect At the guidance the For $XXX leverage. to range, range XX.X%, this to XX%. we primarily a adjusted operating now prior currency adjusted of of $X.XX basis share, EBITDA, expense per to increasing EPS improve XX%. expected the million. foreign we Compared to to $XXX in the last reflects to year X% still be our and million growth to rates midpoint guidance $X.XX over and $X.XX up by improved are year, margins from diluted are $X.XX, full range points of to our X% to And expected of XX year
and operations respectively. free $XX million from flow cash flow our $X in revisions upward made by and million, cash we Lastly,
debt We reduction $XXX X.X year to $XX an to million payments have turn full ratio estimated in guidance now the year debt million, by I'll EBITDA. approximately estimated of the from times increased prior adjusted total back Joe. our call leverage resulting bringing
